TR201901228T4 - Vortioksetin piroglutamat. - Google Patents

Vortioksetin piroglutamat. Download PDF

Info

Publication number
TR201901228T4
TR201901228T4 TR2019/01228T TR201901228T TR201901228T4 TR 201901228 T4 TR201901228 T4 TR 201901228T4 TR 2019/01228 T TR2019/01228 T TR 2019/01228T TR 201901228 T TR201901228 T TR 201901228T TR 201901228 T4 TR201901228 T4 TR 201901228T4
Authority
TR
Turkey
Prior art keywords
vortioxetine pyroglutamate
vortioxetine
pyroglutamate
salt
pharmaceutical compositions
Prior art date
Application number
TR2019/01228T
Other languages
English (en)
Inventor
Lopez De Diego Heidi
Lasse Christensen Kim
Holm Rene
Kateb Jens
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55963369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201901228(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of TR201901228T4 publication Critical patent/TR201901228T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Mevcut buluş, vortioksetin piroglutamat tuzu ve söz konusu tuzu içeren farmasötik bileşimleri sağlamaktadır.
TR2019/01228T 2015-05-13 2016-05-11 Vortioksetin piroglutamat. TR201901228T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201500284 2015-05-13

Publications (1)

Publication Number Publication Date
TR201901228T4 true TR201901228T4 (tr) 2019-02-21

Family

ID=55963369

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01228T TR201901228T4 (tr) 2015-05-13 2016-05-11 Vortioksetin piroglutamat.

Country Status (43)

Country Link
US (2) US10287261B2 (tr)
EP (1) EP3294719B1 (tr)
JP (1) JP6731001B2 (tr)
KR (1) KR102551429B1 (tr)
CN (1) CN107567440B (tr)
AR (1) AR104591A1 (tr)
AU (1) AU2016259762B2 (tr)
BR (1) BR112017024039B8 (tr)
CA (1) CA2984615C (tr)
CL (1) CL2017002844A1 (tr)
CO (1) CO2017011295A2 (tr)
CR (1) CR20170506A (tr)
CY (1) CY1121171T1 (tr)
DK (1) DK3294719T3 (tr)
DO (1) DOP2017000260A (tr)
EA (1) EA032363B1 (tr)
EC (1) ECSP17074919A (tr)
ES (1) ES2709362T3 (tr)
GE (1) GEP20197020B (tr)
HK (1) HK1252099B (tr)
HR (1) HRP20190089T1 (tr)
HU (1) HUE042893T2 (tr)
IL (1) IL255466B (tr)
JO (1) JO3456B1 (tr)
LT (1) LT3294719T (tr)
MA (1) MA43397A (tr)
ME (1) ME03312B (tr)
MX (1) MX2017014390A (tr)
MY (1) MY184965A (tr)
PE (1) PE20180039A1 (tr)
PH (1) PH12017502028A1 (tr)
PL (1) PL3294719T3 (tr)
PT (1) PT3294719T (tr)
RS (1) RS58263B1 (tr)
RU (1) RU2713889C2 (tr)
SI (1) SI3294719T1 (tr)
SV (1) SV2017005560A (tr)
TN (1) TN2017000453A1 (tr)
TR (1) TR201901228T4 (tr)
TW (1) TWI700276B (tr)
UA (1) UA120779C2 (tr)
WO (1) WO2016180870A1 (tr)
ZA (1) ZA201707337B (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US11377416B2 (en) * 2017-07-31 2022-07-05 Small Pharma Ltd. Crystalline forms of hydroxynorketamine
GB201715950D0 (en) * 2017-10-02 2017-11-15 Croda Int Plc Gel composition comprising a phase change material
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1006728A (en) * 1962-12-31 1965-10-06 Mundipharma Ag Amine salts of pyrrolidone carboxylic acid
JPS6160620A (ja) 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
US4780667A (en) 1985-06-25 1988-10-25 Hewlett-Packard Company Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
JP2000516222A (ja) 1996-08-15 2000-12-05 ロザン ファルマ ゲゼルシャフトミットベシュレンクテル ハフツング 嚥下が容易な経口医薬組成物
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ATE516019T1 (de) 2004-05-11 2011-07-15 Egalet Ltd Quellbare dosierform mit gellan-gummit
KR101627901B1 (ko) * 2006-06-16 2016-06-13 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
DK2421534T3 (da) * 2009-04-24 2014-10-13 Lundbeck & Co As H Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin
UA105057C2 (uk) * 2009-08-24 2014-04-10 Х. Луннбек А/С Композиція 1-[2-(2,4-диметилфенілсульфаніл)феніл]-піперазину
JP5787882B2 (ja) * 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
CN104797566B (zh) * 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
MA38338B1 (fr) 2013-02-22 2018-10-31 H Lundbeck As Procédé de fabrication de vortioxétine

Also Published As

Publication number Publication date
PT3294719T (pt) 2019-02-07
RU2713889C2 (ru) 2020-02-10
BR112017024039B1 (pt) 2023-07-04
MY184965A (en) 2021-04-30
JP6731001B2 (ja) 2020-07-29
US20160368884A1 (en) 2016-12-22
TN2017000453A1 (en) 2019-04-12
KR20180006909A (ko) 2018-01-19
GEP20197020B (en) 2019-09-25
BR112017024039A2 (pt) 2018-07-24
CN107567440A (zh) 2018-01-09
HK1252099A1 (zh) 2019-05-17
IL255466A (en) 2018-01-31
MA43397A (fr) 2018-03-21
BR112017024039B8 (pt) 2023-10-31
SI3294719T1 (sl) 2019-03-29
HRP20190089T1 (hr) 2019-02-22
ZA201707337B (en) 2019-02-27
ES2709362T3 (es) 2019-04-16
PH12017502028A1 (en) 2018-04-02
RU2017139002A3 (tr) 2019-08-30
SV2017005560A (es) 2018-02-23
AU2016259762B2 (en) 2020-03-19
EA201792262A1 (ru) 2018-04-30
LT3294719T (lt) 2019-02-11
MX2017014390A (es) 2018-03-23
TWI700276B (zh) 2020-08-01
AR104591A1 (es) 2017-08-02
AU2016259762A1 (en) 2017-11-16
CA2984615A1 (en) 2016-11-17
US10287261B2 (en) 2019-05-14
RS58263B1 (sr) 2019-03-29
CA2984615C (en) 2023-06-13
PE20180039A1 (es) 2018-01-09
CL2017002844A1 (es) 2018-05-11
ME03312B (me) 2019-10-20
CO2017011295A2 (es) 2018-02-20
PL3294719T3 (pl) 2019-04-30
JP2018515520A (ja) 2018-06-14
CN107567440B (zh) 2021-06-22
CY1121171T1 (el) 2020-05-29
TW201706255A (zh) 2017-02-16
HK1252099B (zh) 2020-02-07
WO2016180870A1 (en) 2016-11-17
JO3456B1 (ar) 2020-07-05
HUE042893T2 (hu) 2019-07-29
DK3294719T3 (en) 2019-02-25
EA032363B1 (ru) 2019-05-31
EP3294719A1 (en) 2018-03-21
KR102551429B1 (ko) 2023-07-04
DOP2017000260A (es) 2018-02-28
UA120779C2 (uk) 2020-02-10
EP3294719B1 (en) 2019-01-02
RU2017139002A (ru) 2019-06-13
CR20170506A (es) 2018-02-08
US20190210987A1 (en) 2019-07-11
IL255466B (en) 2022-07-01
ECSP17074919A (es) 2018-02-28
US11279682B2 (en) 2022-03-22

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
BR112016023628A2 (pt) composições farmacêuticas.
TR201901228T4 (tr) Vortioksetin piroglutamat.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
DK3402782T3 (da) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decanderivater
DK3582629T3 (da) Marinade
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
IT201600084952A1 (it) Coglifrutta.
ES1150114Y (es) Abarcón.
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
EA201791716A1 (ru) Фармацевтический состав
DK3424500T3 (da) Farmaceutisk sammensætning, der omfatter famitinib
ITUA20163609A1 (it) "micro-cogeneratore".
IT201700118826A1 (it) giandujamarcobava.it
ES1213664Y (es) Blanco
CL2018000776A1 (es) Composicion agroquimica.
IT201700105412A1 (it) Compressore alternativo.
IT201700057904U1 (it) Espositore combinato per oggetti.
EA201792492A1 (ru) Aml-антигены и их применение
BR112018004657A2 (pt) composições ativas de alto ph.
IT201700059470U1 (it) Mescolatrice.
IT201700059446A1 (it) Mescolatrice.
IT201700047063U1 (it) Imballaggio perfezionato.